anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: It is necessary to harmonize and standardize data variables used in case report forms (CRFs) of clinical studies to facilitate the merging and sharing of the collected patient data across several clinical studies. This is particularly true for clinical studies that focus on infectious diseases. Public health may be highly dependent on the findings of such studies. Hence, there is an elevated urgency to generate meaningful, reliable insights, ideally based on a high sample number and quality data. The implementation of core data elements and the incorporation of interoperability standards can facilitate the creation of harmonized clinical data sets.
OBJECTIVE: This study's objective was to compare, harmonize, and standardize variables focused on diagnostic tests used as part of CRFs in 6 international clinical studies of infectious diseases in order to, ultimately, then make available the panstudy common data elements (CDEs) for ongoing and future studies to foster interoperability and comparability of collected data across trials.
METHODS: We reviewed and compared the metadata that comprised the CRFs used for data collection in and across all 6 infectious disease studies under consideration in order to identify CDEs. We examined the availability of international semantic standard codes within the Systemized Nomenclature of Medicine - Clinical Terms, the National Cancer Institute Thesaurus, and the Logical Observation Identifiers Names and Codes system for the unambiguous representation of diagnostic testing information that makes up the CDEs. We then proposed 2 data models that incorporate semantic and syntactic standards for the identified CDEs.
RESULTS: Of 216 variables that were considered in the scope of the analysis, we identified 11 CDEs to describe diagnostic tests (in particular, serology and sequencing) for infectious diseases: viral lineage/clade; test date, type, performer, and manufacturer; target gene; quantitative and qualitative results; and specimen identifier, type, and collection date.
CONCLUSIONS: The identification of CDEs for infectious diseases is the first step in facilitating the exchange and possible merging of a subset of data across clinical studies (and with that, large research projects) for possible shared analysis to increase the power of findings. The path to harmonization and standardization of clinical study data in the interest of interoperability can be paved in 2 ways. First, a map to standard terminologies ensures that each data element's (variable's) definition is unambiguous and that it has a single, unique interpretation across studies. Second, the exchange of these data is assisted by "wrapping" them in a standard exchange format, such as Fast Health care Interoperability Resources or the Clinical Data Interchange Standards Consortium's Clinical Data Acquisition Standards Harmonization Model.
Participants are required to take a capsule containing 500mg L-carnitine/day continuous for 7-10 days. During the intervention, participants are asked to collect urine sample and dietary record each day. Blood and fecal samples will be collected before and after the intervention. Each participant needs to complete a food frequency questionnaire.
The participants were subjected to a 15-minute training session, once a day for 5 consecutive days. HTC VIVE Pro (HTC Corporation, New Taipei, Taiwan) goggles and accessories were used. It is specialized equipment consisting of a high-resolution screen goggles and headphones, using an Intel WiGig Wireless connection, and the technology allows for free 360 degrees of movement. The interaction in virtual reality is performed using two controllers held by the player. The movement of the controllers and goggles is tracked by two sensors. The game area covered about 5m2, in the form of a rectangle, determined by the location of motion sensors, as recommended by the manufacturer. The participant received visual information when approaching the boundaries of the game field. A Beat Saber music game was used to conduct training sessions.
PURPOSE:To provide a new compound useful as a synthetic intermediate for a pyridyloxy derivative having excellent gastric acid secretion suppressing action and antiulcer action. CONSTITUTION:A compound of the formula I [R<1> is 3- to 7-membered cyclic aminomethyl, di)1-4C alkyl)aminomethyl or cyano], e.g. 4-(4cyano-2-pyridyl-oxy)-2- butynylamine. The compound of the formula I can be produced by reacting a compound of the formula II with a base (e.g. hydrazine) in a solvent (e.g. methanol) at -20 to +15O deg.C. The compound of the formula I is producible from easily available raw material and specimen with simple operation in high yield.
A method for securing patient identity comprising accessing an electronic medical records database including patient data for a plurality of patients. Each patient in the electronic medical records database is assigned a unique patient identifier. Patient data for a first patient, including a first patient identifier, is retrieved from the electronic medical records database. The first patient is de-identified from the patient data. De-identifying includes the creation of a first encoded patient identifier responsive to the first patient identifier. The de-identifying results in de-identified first patient data and includes the replacement of the first patient identifier with the first encoded patient identifier. The de-identified first patient data is transmitted to a data warehouse system. The method further comprises identifying a second patient in response to receiving report data that includes a second encoded patient identifier from the data warehouse system. The identifying includes the creation of a second patient identifier responsive to the second encoded patient identifier.
The failure of relapses and white matter lesions to properly explain long-term disability and progression in multiple sclerosis is compounded by its artificial separation into relapsing remitting, secondary progressive, and primary progressive pigeonholes. The well-known epidemiological disconnection between relapses and long-term disability progression has been rediscovered as "progression independent of relapse activity", i.e. smouldering multiple sclerosis. This smouldering associated worsening proceeds despite early and prolonged use of disease modification therapies, even those that are highly effective at preventing relapses and new/enhancing white matter lesions on MRI. We recognise that smouldering associated worsening and relapse/lesion associated worsening coexist, to varying extents. The extent of cortical demyelination has been shown to correlate significantly with the severity of diffuse injury in normal appearing white matter (post mortem histopathologically (r = 0.55; P = 0.001), and in vivo with MRI (r = -0.6874; P = 0.0006)) and does so independently of white matter lesion burden. Axon loss in the normal appearing white matter explains disability in multiple sclerosis better than focal white matter lesions do. Smouldering associated worsening typically manifests as a length-dependent central axonopathy. We propose a unifying model for multiple sclerosis pathogenesis, wherein accumulation of cortical lesion burden predisposes associated normal appearing white matter to diffuse injury, whilst also intensifying damage within white matter lesions. Our novel two-hit hypothesis implicates cortical disease as a culprit for smouldering multiple sclerosis, abetted by active focal inflammation in the white matter (and vice versa). Substantiation of the two-hit hypothesis would advance the importance of specific therapeutic intervention for (and monitoring of) cortical/meningeal inflammation in people with multiple sclerosis.
OBJECTIVE: Contaminated duodenoscopes caused several hospital outbreaks. Despite efforts to reduce contamination rates, 15% of patient-ready duodenoscopes are still contaminated with gastrointestinal microorganisms. This study aimed to provide an overview of duodenoscope contamination over time, identify risk factors and study the effects of implemented interventions.
DESIGN: Duodenoscope culture sets between March 2015 and June 2022 at a Dutch tertiary care centre were analysed. Contamination was defined as (1) the presence of microorganisms of oral or gastrointestinal origin (MGO) or (2) any other microorganism with ≥20 colony-forming units/20 mL (AM20). A logistic mixed effects model was used to identify risk factors and assess the effect of interventions, such as using duodenoscopes with disposable caps, replacing automated endoscope reprocessors (AER) and conducting audits in the endoscopy department.
RESULTS: A total of 404 culture sets were analysed. The yearly contamination rate with MGO showed great variation, ranging from 14.3% to 47.5%. Contamination with AM20 increased up to 94.7% by 2022. For both MGO and AM20, the biopsy and suction channels were the most frequently contaminated duodenoscope components. The studied interventions, including audits, AER replacement and implementation of duodenoscopes with disposable caps, did not show a clear association with contamination rates.
CONCLUSION: Duodenoscope contamination remains a significant problem, with high contamination rates despite several interventions. Reprocessing the biopsy and suction channels is especially challenging. Changes in the design of reusable duodenoscopes, such as enabling sterilisation or easily replaceable channels, are necessary to facilitate effective duodenoscope reprocessing and to eliminate the risk of duodenoscope-associated infections.
The study was conducted to determine the effect of video education on anxiety level before the ERCP procedure and satisfaction degree after the ERCP procedure between September 1st 2017 and December 31st 2018 at Bagcilar Medipol Mega University Hospital. Patients were grouped into two in a randomized manner. In control arm, patients underwent ERCP procedure with the information provided by the gastroenterologist who recommended the procedure. Patients in experimental arm, besides the information provided by the gastroenterologist, watched video of ERCP procedure and answered all the questions about the procedure by an experienced nurse. A total of 70 patients (35 in each arms) was planned to enroll to the study. State-Trait Anxiety Inventory (STAI) form was applied to measure anxiety level and visual analog score (VAS) was applied to measure the satisfaction about the procedure.
Participants receive pembrolizumab 200 mg every 3 weeks (Q3W) plus oxaliplatin 130 mg/m\^2 Q3W by intravenous (IV) infusion plus TS-1 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course, and will continue for up to \~3 years.
At-Home (Maintenance Therapy) Dosing Instructions

The first injections of edex® must be done at the physician's office by medically trained personnel. Self-injection therapy by the patient can be started only after the patient is properly instructed and well trained in the self-injection technique. The physician should instruct the patient to discard any needles which become bent during the self-injection procedure as these needles may break. The physician should make a careful assessment of the patient's skills and competence with the self-injection procedure. The intracavernous injection must be done under sterile conditions. The site of injection is usually along the lateral aspect of the proximal third of the penis. Visible veins should be avoided. The side of the penis that is injected and the site of injection must be alternated. The injection site must be cleansed with an alcohol swab before injection.

The dose of edex® that is selected for self-injection treatment should provide the patient with an erection that is satisfactory for sexual intercourse and that is maintained for no longer than 1 hour. If the duration of erection is longer than 1 hour, the dose of edex® should be reduced. The lowest effective dose should be used at home. Self-injection therapy for use at home should be initiated at the dose that was determined in the physician's office. Dose adjustment may be required and should be made only after consultation with the physician.

Careful and continuous follow-up of the patient while in the self-injection program must be exercised. This is especially true for the initial self-injections, since adjustments in the dose of edex® may be needed. The recommended frequency of injection is no more than 3 times weekly, with at least 24 hours between each dose. The reconstituted edex® cartridge and needle are intended for single use only and should be discarded after use. The user should be instructed in the proper disposal of the needles and cartridges.

While on self-injection treatment, it is recommended that the patient visit the prescribing physician's office every 3 months. At that time, the efficacy and safety of the therapy should be assessed, and the dose of edex® should be adjusted, if needed.

The patient is instructed to follow the enclosed patient information pamphlet.
Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
PURPOSE: To provide a pharmaceutical prepn. or nutritive prepn. for treating or prophylaxis of the high-homocysteine level symptom and/or high-methionine level symptom of the infant's blood or the pathological disorder associated therewith. CONSTITUTION: This prepn. contains a) the vitamin B6 itself, at least part of which is a compd. for easily releasing pyridoxal (PL) in the body without the intervention of the PL or oxdase enzyme or oxygen or the vitamin B6 having the form of the salt of a medicinally permissible acid, which is an active raw material, b) folate or the precursor of the folate which releases the folate in the body and c) vitamin B12 which may have an intrinsic factor at ratios of a):b) from 1:25 to 10,000:1 and b):c) from 1:1 to 50,000:1. This prepn. is incorporated into the artificial nutritive mixture for the infants.
The invention comprises compounds of general formula <FORM:0938201/IV(a)/1> wherein A stands for the ethylene radical or an ethylene radical containing a C1-4-alkyl substituent and the broken lines denote optional bonds, and acid addition salts; and their preparation by dehydrating a hydroxy compound of formula <FORM:0938201/IV(a)/2> <FORM:0938201/IV(a)/3> in an organic solvent in the presence of a dehydrating agent or by reacting a halogen-alkylidene compound of formula <FORM:0938201/IV(a)/4> with benzylamine or a C1-4-alkylamine.  Separation of stereoisomeric halogen-substituted compounds is mentioned.  Hydroxy compounds of the second general formula above may be prepared by (1) reacting an appropriate 5-keto compound with an N-alkyl-N-benzyl-aminoalkyl halide as magnesium, lithium or zinc metal derivative followed by hydrolysis and debenzylation by hydrogenolysis of the resulting 5-hydroxy-5-(N-alkyl-N-benzyl)aminoalkyl compound; (2) reacting an appropriate 5-keto compound with a compound of formula <FORM:0938201/IV(a)/5> followed by hydrolysis and then by hydrogenation of the triple bond of the resulting 5-hydroxy- 5-(N- alkyl- N-benzyl)amino-alkynyl compound to form a 5-hydroxy-5-JN-alkyl- N-benzyl)- aminoalkyl compound which can be debenzylated by hydrogenolysis; (3) reacting an appropriate 5-keto compound with an ethyl magnesium halide, dehydrating the resulting carbinol and oxidising the consequent ethylidene group to the 5-acetyl compound which is reacted with an appropriate amine and aldehyde and then catalytically reduced.  Halogeno-alkylidene compounds of the third general formula above are prepared by the following steps; (1) reacting an appropriate 5-keto compound with an etherified hydroxy-propyl halide or a propenyl halide as organo-magnesium derivative, to form on hydrolysis the corresponding 5-hydroxy-5-substituted compound which is then subjected to simultaneous dehydration and halogenation e.g. with hydrobromic acid or phosphorus oxychloride. p  1-Chloro-2-methyl- 3-(N-methyl- N-benzyl)-aminopropane is prepared from the corresponding 3-bromopropane and amine.  Compositions having activity on the central nervous system comprise a compound or salt of the invention in association with a compatible pharmaceutical carrier.  Enteral and parenteral administration of solid (tablets, capsules, dragees, suppositories) and liquid (solutions, suspensions, emulsions) preparations is mentioned.
The invention discloses a disposable medical hydrogel eye mask, and belongs to the field of medicine. The disposable medical hydrogel eye mask comprises a substrate layer and an isolation layer, wherein a base material is arranged between the substrate layer and the isolation layer and comprises polyacrylate sodium, aluminium trichloride, EDTA (ethylene diamine tetraacetic acid) disodium salt, tartaric acid or citric acid, water-soluble macromolecules, medical glycerin, medicine extractive substances and pure water. The disposable medical hydrogel eye mask has good shape following performance and adhesion performance, and the comfort degree is high. The macromolecular reticular structure gel can release moisture, can achieve the physical isolation and shielding effects on the eyes, can maintain the eyes to be in a relatively sealed and high-humidity environment, and can prevent xerosis corneae secondary inflammatory reaction. The disposable medical hydrogel eye mask is used for being pasted on the outer sides of the eyes of a general anesthesia operation patient for providing the relatively sealed and humid environment for the patient and preventing the exposure keratitis. Rough brake herbs, araliae cardatae, matsumura leafflower herbs, fleshy spurge leaves and ternate buttercup roots are mutually matched; the anti-bacterial and anti-inflammatory effects and the toxicity removing and detumescence functions are achieved; the heeling speed of the postoperative patient is accelerated; in addition, the inflammation can be better prevented.
The primary objective of this research study is to improve outcomes involving core social-communication symptoms for young children with ASD by increasing access to clinically validated early behavioral intervention through a telehealth parent coaching model. The investigators will test the hypothesis that telehealth-delivered Naturalistic Developmental Behavioral Intervention parent coaching (TC) is non-inferior to in-person coaching (IPC) for the treatment of core social-communication symptoms in toddlers with ASD. The secondary hypothesis is that feasibility (defined as parent fidelity) of TC is non-inferior to IPC. An exploratory objective is to guide clinical decision-making for telehealth implementation by examining the heterogeneity of treatment response across the two treatment arms. The investigators will test the hypothesis that baseline child behavioral dysregulation, active engagement, developmental quotient, and parent stress moderate child social-communication outcomes.

After completing eligibility testing, eligible children will be randomized into the TC or IPC condition. Each condition will involve twice weekly coaching sessions over 12 weeks. At the end of the twelve weeks, participants will be reassessed.
Healthy male and female volunteers. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 30 days.
AIMS: Septic cardiomyopathy is characterized by impaired contractile function and mitochondrial activity dysregulation. Salvianolic acid B (Sal B) is a potent therapeutic compound derived from the traditional Chinese medicine Salvia miltiorrhiza. This study explored the protective effects of Sal B on septic heart injury, emphasizing the mitochondrial unfolded protein response (UPRmt).
MATERIALS AND METHODS: An in vivo mouse model of lipopolysaccharide (LPS)-induced heart injury was utilized to assess Sal B's protective role in septic cardiomyopathy. Additionally, cell models stimulated by LPS were developed to investigate the mechanisms of Sal B on UPRmt. Quantitative polymerase chain reaction, western blotting, immunohistochemistry, and immunofluorescence were employed for molecular analysis.
RESULTS: Sal B, administered at doses of 10, 30, and 60 mg/kg, demonstrated protective effects on cardiac contractile function, reduced heart inflammation, and mitigated cardiac injury in LPS-exposed mice. In cardiomyocytes, LPS induced apoptosis, elevated mitochondrial ROS levels, promoted mitochondrial fission, and decreased mitochondrial membrane potential, all of which were alleviated by Sal B. Mechanistically, Sal B was found to induce UPRmt both in vivo and in vitro. ATF5, identified as a UPRmt activator, was modulated by LPS and Sal B, resulting in increased ATF5 expression and its translocation from the cytosol to the nucleus. ATF5-siRNA delivery reversed UPRmt upregulation, exacerbating mitochondrial dysfunction in LPS-stimulated cardiomyocytes and counteracting the mitochondrial function enhancement in Sal B-treated cardiomyocytes.
CONCLUSIONS: This study provides evidence that Sal B confers cardiac protection by enhancing UPRmt, highlighting its potential as a therapeutic approach for mitigating mitochondrial dysfunction in septic cardiomyopathy.
The invention discloses a marine fish probiotic lactococcus lactis strain and application thereof. The strain is lactococcus lactis (L.lactis) M48, and the preservation number is: GDMCC No. 62621. In vitro experiments prove that: the lactococcus lactis M48 is co-cultured with sea bass cells infected by sea bass iridovirus (SPIV), and has the characteristic of resisting the proliferation of the SPIV in the sea bass cells in vitro; the lactococcus lactis M48 also has an inhibitory effect on sea fish vibrio vulnificus, vibrio harveyi, vibrio alginolyticus, streptococcus ragmitis, citrobacter and Aeromonas. Animal experiments prove that: lactococcus lactis M48 has the characteristics of immunoregulation and immunity enhancement for sea bass, and M48 strain alone has the characteristics of anti-SPIV infection for sea bass. The lactococcus lactis M48 has a certain application prospect in the aspects of resisting viruses and pathogenic bacteria of marine fish, regulating immunity and enhancing the immune function of the marine fish.
Standard of care consist of 75 mg of Oseltamivir for five days and any other required provision of care. These will be determined on case by case basis by research clinician.
Test coronary endothelial function before after hookah smokers smoke charcoal-heated hookah and before and after age-matched cigarette smokers smoke 2 cigarettes. In the same subjects, we will test for acute smoking-induced changes in LV wall strain by speckle tracking. Finally, in a subset of subjects we will repeat the MCE and speckle tracking studies after pretreatment with either i.v. vitamin C or one dose of oral tadalafil.